Veltassa Powder, For Suspension
NDC Package 53436-252-30
Package Information
Veltassa (patiromer) powders is a medication used to treat a high level of potassium in your blood. This formulation utilizes a powder, for suspension delivery system. Marketed by Vifor Pharma, Inc., this product is identified by NDC 53436-252 and is authorized under FDA application NDA205739.
Identification & Billing
- RxCUI: 1716209 - patiromer 8.4 GM Powder for Oral Suspension
- RxCUI: 1716209 - patiromer 8400 MG Powder for Oral Suspension
- RxCUI: 1716215 - Veltassa 8.4 GM Powder for Oral Suspension
- RxCUI: 1716215 - patiromer 8400 MG Powder for Oral Suspension [Veltassa]
- RxCUI: 1716215 - Veltassa 8400 MG Powder for Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 53436 - Vifor Pharma, Inc.
- 53436-252 - Veltassa
- 53436-252-30 - 30 PACKET in 1 CARTON / 1 POWDER, FOR SUSPENSION in 1 PACKET (53436-252-01)
- 53436-252 - Veltassa
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 53436-252-30 identifies a specific commercial package of 30 packet in 1 carton / 1 powder, for suspension in 1 packet (53436-252-01) of Veltassa, a human prescription drug labeled by Vifor Pharma, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This powder, for suspension is formulated for oral use and contains patiromer as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Vifor Pharma, Inc. on October 23, 2015. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat a high level of potassium in your blood. Too much potassium in your blood can sometimes cause heart rhythm problems. Patiromer helps get rid of extra potassium by binding to it. The potassium then passes out of your body in your stool.
How is this Vifor Pharma, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 53436025230. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.